Stuti Girish Shroff, M.B.,B.S., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glomerulonephritis, IGA | 1 | 2017 | 66 | 0.600 |
Why?
|
| Common Bile Duct Neoplasms | 2 | 2014 | 111 | 0.570 |
Why?
|
| Ampulla of Vater | 2 | 2014 | 141 | 0.560 |
Why?
|
| Fever | 1 | 2024 | 1616 | 0.550 |
Why?
|
| Dyspnea | 1 | 2023 | 1303 | 0.520 |
Why?
|
| Intestinal Neoplasms | 1 | 2017 | 319 | 0.510 |
Why?
|
| Sarcoma, Kaposi | 1 | 2017 | 370 | 0.490 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 146 | 0.440 |
Why?
|
| Barrett Esophagus | 3 | 2023 | 494 | 0.420 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 847 | 0.420 |
Why?
|
| Pancreatic Ducts | 1 | 2013 | 328 | 0.400 |
Why?
|
| Adenocarcinoma | 8 | 2022 | 6364 | 0.400 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2021 | 1634 | 0.390 |
Why?
|
| Esophageal Neoplasms | 4 | 2023 | 1583 | 0.360 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 1142 | 0.310 |
Why?
|
| Arteries | 4 | 1997 | 1119 | 0.300 |
Why?
|
| Colonic Neoplasms | 3 | 2022 | 2541 | 0.270 |
Why?
|
| Neuroendocrine Tumors | 3 | 2018 | 594 | 0.270 |
Why?
|
| Melanoma | 1 | 2024 | 5510 | 0.260 |
Why?
|
| Crohn Disease | 1 | 2017 | 2303 | 0.250 |
Why?
|
| Cell Lineage | 1 | 2013 | 2504 | 0.250 |
Why?
|
| Pancreatic Neoplasms | 3 | 2021 | 5256 | 0.250 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2022 | 506 | 0.250 |
Why?
|
| Stomach Neoplasms | 4 | 2020 | 1333 | 0.240 |
Why?
|
| Models, Cardiovascular | 4 | 1997 | 996 | 0.220 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2022 | 55 | 0.210 |
Why?
|
| Ventricular Function, Left | 4 | 1999 | 3670 | 0.200 |
Why?
|
| Nerve Tissue | 1 | 2021 | 79 | 0.190 |
Why?
|
| Glutamine | 1 | 2023 | 578 | 0.190 |
Why?
|
| Carcinoma | 2 | 2022 | 2375 | 0.190 |
Why?
|
| Carotid Body Tumor | 1 | 2020 | 32 | 0.180 |
Why?
|
| Bile Acids and Salts | 1 | 2022 | 367 | 0.180 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2021 | 358 | 0.170 |
Why?
|
| Neck Dissection | 1 | 2020 | 197 | 0.170 |
Why?
|
| Albumins | 1 | 2021 | 569 | 0.160 |
Why?
|
| Paraganglioma | 1 | 2020 | 143 | 0.160 |
Why?
|
| Gastritis, Atrophic | 1 | 2018 | 31 | 0.160 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 697 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2020 | 604 | 0.150 |
Why?
|
| Colonic Polyps | 1 | 2022 | 542 | 0.150 |
Why?
|
| Extracellular Space | 1 | 1999 | 594 | 0.140 |
Why?
|
| Acidosis | 1 | 1999 | 270 | 0.140 |
Why?
|
| Lithotripsy, Laser | 1 | 1996 | 46 | 0.140 |
Why?
|
| Laryngeal Neoplasms | 1 | 2020 | 512 | 0.140 |
Why?
|
| Diagnosis, Differential | 4 | 2023 | 12959 | 0.140 |
Why?
|
| Inhibins | 1 | 2017 | 211 | 0.140 |
Why?
|
| Cytogenetic Analysis | 1 | 2017 | 295 | 0.140 |
Why?
|
| Adenomatous Polyps | 1 | 2017 | 107 | 0.140 |
Why?
|
| Ureteral Calculi | 1 | 1996 | 110 | 0.130 |
Why?
|
| Myocardial Contraction | 2 | 1999 | 1585 | 0.130 |
Why?
|
| Diarrhea | 1 | 2022 | 1348 | 0.130 |
Why?
|
| Receptor, Notch1 | 1 | 2017 | 502 | 0.120 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 547 | 0.120 |
Why?
|
| Paclitaxel | 1 | 2021 | 1708 | 0.120 |
Why?
|
| Disease Progression | 5 | 2023 | 13284 | 0.120 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 4253 | 0.120 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2014 | 503 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2021 | 1809 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2017 | 739 | 0.110 |
Why?
|
| Prednisone | 1 | 2017 | 1574 | 0.110 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 6773 | 0.110 |
Why?
|
| 14-alpha Demethylase Inhibitors | 1 | 2011 | 4 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2017 | 602 | 0.100 |
Why?
|
| Aorta | 3 | 1997 | 2061 | 0.100 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 2011 | 52 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2022 | 1591 | 0.100 |
Why?
|
| Cyclin D1 | 1 | 2014 | 463 | 0.100 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 553 | 0.100 |
Why?
|
| Clotrimazole | 1 | 2011 | 77 | 0.100 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 567 | 0.100 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 516 | 0.100 |
Why?
|
| Adenoma | 1 | 2022 | 2174 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 1863 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 3 | 2022 | 1613 | 0.090 |
Why?
|
| Resuscitation | 1 | 1995 | 658 | 0.090 |
Why?
|
| Rabbits | 4 | 1999 | 4894 | 0.090 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 11366 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 9438 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 2214 | 0.090 |
Why?
|
| Humans | 31 | 2024 | 744343 | 0.090 |
Why?
|
| Liver Transplantation | 1 | 2020 | 2119 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 2728 | 0.080 |
Why?
|
| Male | 18 | 2023 | 350118 | 0.080 |
Why?
|
| Shock, Septic | 1 | 1995 | 775 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 783 | 0.080 |
Why?
|
| Stroke Volume | 2 | 1999 | 5007 | 0.080 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2022 | 2043 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 1790 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2013 | 643 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3255 | 0.070 |
Why?
|
| Young Adult | 4 | 2023 | 56430 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 6895 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 2942 | 0.070 |
Why?
|
| Blood Volume | 2 | 1999 | 565 | 0.070 |
Why?
|
| Middle Aged | 13 | 2024 | 213383 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2021 | 1619 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 2133 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 3086 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2023 | 2948 | 0.070 |
Why?
|
| Female | 17 | 2024 | 380194 | 0.060 |
Why?
|
| Lung | 1 | 2023 | 9856 | 0.060 |
Why?
|
| Blood Pressure | 2 | 1996 | 8554 | 0.060 |
Why?
|
| Neoplasms | 2 | 2023 | 21683 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6538 | 0.050 |
Why?
|
| Vascular Resistance | 2 | 1995 | 936 | 0.050 |
Why?
|
| Glutamates | 1 | 2023 | 398 | 0.050 |
Why?
|
| Agrin | 1 | 2022 | 68 | 0.050 |
Why?
|
| Prognosis | 3 | 2022 | 29063 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2011 | 1353 | 0.050 |
Why?
|
| Proline | 1 | 2023 | 458 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 200 | 0.050 |
Why?
|
| Micelles | 1 | 2022 | 203 | 0.050 |
Why?
|
| Registries | 1 | 2017 | 8089 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 17446 | 0.050 |
Why?
|
| Permeability | 1 | 2022 | 738 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2023 | 566 | 0.050 |
Why?
|
| Hoarseness | 1 | 2020 | 65 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3586 | 0.040 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 57776 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2021 | 528 | 0.040 |
Why?
|
| Compliance | 2 | 1997 | 104 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 3507 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 426 | 0.040 |
Why?
|
| Mucins | 1 | 2022 | 564 | 0.040 |
Why?
|
| Computational Biology | 2 | 2021 | 3521 | 0.040 |
Why?
|
| Biopsy | 2 | 2023 | 6756 | 0.040 |
Why?
|
| Leucovorin | 1 | 2020 | 628 | 0.040 |
Why?
|
| Adult | 10 | 2022 | 214055 | 0.040 |
Why?
|
| Aged | 8 | 2021 | 163280 | 0.040 |
Why?
|
| Organ Preservation | 1 | 2020 | 331 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2021 | 826 | 0.040 |
Why?
|
| Metaplasia | 1 | 2018 | 313 | 0.040 |
Why?
|
| Vasomotor System | 1 | 1997 | 209 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2022 | 1038 | 0.040 |
Why?
|
| Gastroscopy | 1 | 2018 | 207 | 0.040 |
Why?
|
| Mathematics | 1 | 1997 | 728 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2017 | 163 | 0.030 |
Why?
|
| Perfusion | 1 | 2020 | 1360 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2021 | 63114 | 0.030 |
Why?
|
| Liver | 2 | 2022 | 7474 | 0.030 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1997 | 235 | 0.030 |
Why?
|
| Pressure | 1 | 1999 | 1203 | 0.030 |
Why?
|
| Diastole | 1 | 1997 | 791 | 0.030 |
Why?
|
| Nitroprusside | 1 | 1995 | 275 | 0.030 |
Why?
|
| Ligands | 1 | 2022 | 3282 | 0.030 |
Why?
|
| Hemodynamics | 2 | 1995 | 4199 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 12354 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2021 | 1211 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 1915 | 0.030 |
Why?
|
| Animals | 7 | 2022 | 168757 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1782 | 0.030 |
Why?
|
| Vasodilation | 1 | 1997 | 944 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 2503 | 0.030 |
Why?
|
| Elasticity | 1 | 1995 | 657 | 0.030 |
Why?
|
| Gastrectomy | 1 | 2018 | 663 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2017 | 447 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3527 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 365 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 3616 | 0.030 |
Why?
|
| Endotoxins | 1 | 1995 | 527 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 713 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 1997 | 1686 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 1995 | 597 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 1850 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 11031 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1995 | 1525 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 1641 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 2886 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 8428 | 0.020 |
Why?
|
| Mesoderm | 1 | 2013 | 686 | 0.020 |
Why?
|
| Dogs | 1 | 1995 | 3912 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2017 | 975 | 0.020 |
Why?
|
| Catheterization | 1 | 1995 | 1470 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2017 | 1547 | 0.020 |
Why?
|
| Adolescent | 4 | 2020 | 85781 | 0.020 |
Why?
|
| Stomach | 1 | 2013 | 697 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2017 | 77449 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2023 | 10481 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2022 | 9146 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1434 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 1213 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 2759 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 2734 | 0.020 |
Why?
|
| Rats | 1 | 2022 | 24260 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 1995 | 2046 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 39050 | 0.020 |
Why?
|
| Stents | 1 | 1996 | 3280 | 0.020 |
Why?
|
| Models, Biological | 1 | 2021 | 9583 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4751 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2017 | 10252 | 0.010 |
Why?
|
| Length of Stay | 1 | 1996 | 6309 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 12072 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 18029 | 0.010 |
Why?
|
| Cell Survival | 1 | 2011 | 5882 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 15076 | 0.010 |
Why?
|
| Contrast Media | 1 | 2013 | 5300 | 0.010 |
Why?
|
| Time Factors | 2 | 1999 | 40075 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 25043 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11524 | 0.010 |
Why?
|
| Phenotype | 1 | 2017 | 16365 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 15519 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20129 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2011 | 13033 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 1997 | 332 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2017 | 23338 | 0.010 |
Why?
|
| Pregnancy | 1 | 1997 | 29144 | 0.010 |
Why?
|
| Atenolol | 1 | 1995 | 100 | 0.010 |
Why?
|
| Hypertension | 1 | 1995 | 8480 | 0.010 |
Why?
|
| Ramipril | 1 | 1995 | 95 | 0.010 |
Why?
|
| Nifedipine | 1 | 1995 | 226 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 23403 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 81183 | 0.010 |
Why?
|
| Echocardiography | 2 | 1997 | 5102 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1997 | 1423 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 35421 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 1995 | 458 | 0.010 |
Why?
|
| Risk Factors | 1 | 2018 | 72290 | 0.010 |
Why?
|
| Reference Values | 1 | 1997 | 4982 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1995 | 2029 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1995 | 3913 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1995 | 6365 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1995 | 12026 | 0.000 |
Why?
|